Pfizer Inc.
NASDAQ: PFEKey stats
Price chart
About Pfizer Inc.
Pharmaceuticals
Company profile
- IPO date
- Jan 17, 1944
- Website
- www.pfizer.com
Healthcare peers
How PFE compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $1004.92 | -0.18% | $946.37B | 37.44 |
 JNJ Johnson & Johnson | $226.71 | -1.77% | $549.56B | 26.34 |
 ABBV AbbVie Inc. | $210.39 | -0.18% | $371.72B | 87.96 |
 UNH UnitedHealth Group | $393.85 | -1.31% | $358.78B | 30.14 |
 MRK Merck & Co. | $111.38 | -1.79% | $275.09B | 30.79 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Pfizer is a pharmaceutical titan with a diverse portfolio that includes the popular COVID-19 vaccine, Comirnaty. Its well-established research and development arm is consistently working on expanding its drug pipeline, promising future growth. The company's current dividend yield of 6.3832% remains a significant attraction for income-seeking investors, particularly in low-interest-rate environments. With a P/E ratio of 19.7, its valuation appears reasonable compared to competitors in the healthcare sector. Furthermore, its low beta of 0.3537 indicates less volatility compared to the broader market, which may appeal to risk-averse investors.
Bear case
Pfizer faces stiff competition from other pharmaceutical giants like Moderna and Johnson & Johnson, potentially impacting market share and revenue growth. The company's reliance on blockbuster drugs like its COVID-19 vaccine introduces risk if demand wanes or if new, superior treatments emerge. Concerns about patent cliffs, where key drug patents expire, pose a threat to sustained revenue. Furthermore, regulatory challenges and the high cost of R&D could impact profitability, especially if key drug approvals face delays or denials. The current price trend is bullish, but any negative shift in sentiment or performance could swiftly change this trajectory.
Who should buy PFE
Pfizer is a solid fit for long-term dividend investors who have a moderate risk tolerance and are seeking stable income through high-yield dividends. It's also suitable for investors looking to add a defensive, large-cap healthcare name with a lower volatility profile to their portfolio.
Key risks
- Intense competition from pharmaceutical peers could affect market share. - Dependency on blockbuster drugs might backfire if demand decreases or competitors provide better alternatives. - Expiring drug patents may lead to revenue erosion. - Regulatory barriers and high R&D costs could hinder profitability.
Where to buy PFE
Open an account with a broker we've reviewed and start trading Pfizer Inc. today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent PFE news
With an annual dividend yield of 6.68%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Dividend Stocks with 5%+ Yields and Growing Cash Flows. On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 from $25. It reiterated an Underperform rating on the shares following what the […]
Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI to adolescents with hemophilia A or B and inhibitors. The decision opens access to a new patient group within the EU hemophilia market for this rare disease therapy. The expanded label highlights bleed protection and a simplified administration regimen for a hard to treat population. For investors watching NYSE:PFE, this update is part of Pfizer's broader push in rare diseases, an area where specialized treatments...
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year.
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.